The NIAID developed a gp350-ferritin nanoparticle vaccine, and studies NCT04645147 and NCT05683834 have been initiated to assess the gp350 glycoprotein-ferritin nanoparticle combined with an adjuvant in healthy adults with or without EBV infection [44]. The gene discussed is ART4; the disease is Epstein-Barr virus infection.